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doi:10.1016/j.pedneo.2010.12.012Traditional treatment of muscular ventricular septal defect (VSD) is surgical closure, but it
carries considerable morbidity and mortality. The Amplatzer muscular VSD occluder
(AGA Medical Corporation, Plymouth, MN, USA) was approved by the United States Food and
Drug Administration in September 2007 and by the Taiwan Department of Health in September
2009. It is a self-expandable double-disc device made from a nitinol wire mesh. Dacron
polyester patches are sewn into each disc and the connecting waist to increase the thrombo-
genicity of the device. Many reports have shown that transcatheter device closure of muscular
VSDs is effective and safe. It has no scar, less pain, shorter hospital stay, and less cost
compared to the traditional open heart surgery.
Copyright ª 2011, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.Muscular ventricular septal defects (VSDs) account for
10e15% of congenital VSDs and can be single or multiple,
existing anywhere in the septum.1 Themost common form of
muscular VSDs is the apical defects, followed by the mid-
muscular defects. Anterior defects are less common, and
multiple muscular VSDs (Swiss cheese muscular septum) are
rare. Acquired muscular VSDs are very rare and usuallynt of Pediatrics, Taichung
ction 3, Chung-Kang Road,
tw.
an Pediatric Association. Publishcaused by acute myocardial infarction or, occasionally, by
trauma. When the defect is large enough to have hemody-
namic significance, closure of the defect is indicated.
Traditional treatment is surgical closure, but it carries
considerable morbidity and mortality, primarily resulting
from technical difficulties associated with inadequate
exposure and incomplete closure.1e3 In some cases, a left
ventriculotomy is needed, which may cause left ventricular
impairment, apical aneurysm, or ventricular arrhythmia.1e3
Moreover, the surgical scar may be a cosmetic concern for
the patients and their parents.
Transcatheter closure of muscular VSD was first reported
by Lock et al4 in 1987 using a Rashkind umbrella device. Sinceed by Elsevier Taiwan LLC. All rights reserved.
4 Y.-C. Futhen, there have been several devices developed, including
the Sideris buttoned device, Gianturco and detachable coils,
and others.5,6 However, these devices were not originally
designed for this purpose, and their widespread use has been
limited by several drawbacks, such as large delivery sheaths,
complex implantation techniques, inability to recapture and
reposition and a high rate of residual shunts.1e3
The Amplatzer Muscular VSD occluder (AGA Medical
Corporation, Plymouth, MN, USA) was approved by the US
Food and Drug Administration in September 2007 and by the
Taiwan Department of Health in September 2009. It is
a self-expandable double-disc device made from a nitinol
wire mesh.1e3,7e9 Dacron polyester patches are sewn into
each disc and the connecting waist to increase the throm-
bogenicity of the device. The device is symmetric, specifi-
cally designed for the muscular VSD. Both the left ventricle
retention skirt and the right ventricle retention disk are
4 mm larger than the waist. The connecting waist is 7-mm
long in regular devices and 10-mm long for the post-
myocardial infarction muscular VSD occluder.
The procedure is preferably performed under general
endotracheal anesthesia with transesophageal echocardio-
graphic guidance.1e3,7e9 Left ventriculography in the left
anterior oblique view defines the location and size of the
VSD. Balloon sizing is not suggested as it carries a certain
risk, and it may not be useful for a nonstretchable muscular
interventricular septum. The appropriate device size is
chosen to be the same or 1e2 mm larger than the VSD size,
measured by transesophageal echocardiographic guidance
or ventriculography. The standard closure procedure is as
follows: A 4 or 5 French Judkins right (Terumo Medical
Corp., Somerset, NJ, USA) or Cobra catheter (Cook Medical,
Bloomington, IN, USA) is used to guide an exchanged-size
Terumo glide wire across the defect into the right ventricle
and then the pulmonary artery or superior vena cava.
Subsequently, the wire is snared and gently pulled out into
the right internal jugular or femoral vein. A long delivery
sheath is then passed over the wire from the vein, across
the defect and then entering the left ventricle. The dilator
and the wire are then removed, and the device is loaded
and deployed. Patients are sent home on the day after the
procedure and take aspirin 3e5 mg/kg daily for 6 months. If
the infant is small in size (<4 kg), precluding safe percu-
taneous closure, or if the VSD is associated with other
defects requiring open surgical repair, closure of the VSD
can be achieved perventricularly in the operating room
before initiation of cardiopulmonary bypass (hybrid
therapy).
The results of initial human experiences are encour-
aging.7e9 In 2004, the United States registry of the Amplatzer
Muscular VSD occluder reported 83 procedures in 75 patients
with a median age of 1.4 years, who underwent percuta-
neous (70 of 75) and/or perventricular (6 of 75) closure of
hemodynamically significant congenital single or multiple
muscular VSDs.10 Thedevicewas implanted successfully in 72
of the 83 (86.7%) procedures. Major procedure- or device-
related complications occurred in 10.7% of the patients.Closure rates were excellent and increased from 47.2% 24
hours post-procedure to 92.3% at 12 months’ follow-up.
These results compare favorably with the surgical results. In
2005, Thanopoulos1 reported intermediate-term outcome in
30 children with single muscular VSD.2 Successful closure of
the defect was achieved in 28 of the 30 patients (93%). Major
complication was noted in only one patient (4.2 kg) who
developed a complete heart block. In 2004, the U.S. registry
of the postinfarction muscular VSD occluder reported on 18
patients.11 The procedure was successful in deploying
a device across the VSD in 16 of the 18 patients. The 30-day
mortality was 28%. Eleven patients are still alive and have
been followed up for a median of 332 days.
In conclusion, transcatheter closure of muscular VSDs
using the Amplatzer muscular VSD occluders is effective
and safe. It has no scar, less pain, shorter hospital stay, and
less cost compared with the traditional open heart surgery.
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